Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease

ConclusionsIn our cohort with suspected DI-ILD, 79% carried one or more genetic variants accompanied by the use of drugs metabolized by a corresponding affected pathway. In 60%, the diagnosis of DI-ILD was likely, whereas in 37.5%, it was highly likely, based on CYP analyses. This study underlines the importance of considering both drug use and genetic make-up as a possible cause, or at least a contributing factor, in the development and/or progression of fibrotic lung diseases.Clinical Trial RegistrationClinicalTrials.gov identifier NCT00267800, registered in 2005.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research